199103-19-0 Usage
Description
1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate, also known as Benzyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate, is a chemical compound that belongs to the class of nitrogen heterocyclic sulfonyl chlorides. It is characterized by its unique chemical structure, which features a benzyloxycarbonyl group attached to a piperidine ring, with a methanesulfonate group at the 4-position. 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE is known for its potential applications in the synthesis of various pharmaceuticals and chemical products.
Uses
Used in Pharmaceutical Industry:
1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate is used as an intermediate for the preparation of conformationally restricted saturated nitrogen heterocyclic sulfonyl chloride. This application is significant because it allows for the development of new pharmaceutical compounds with specific structural features that can potentially enhance their therapeutic properties, such as improved binding affinity, selectivity, and bioavailability.
Used in Chemical Synthesis:
In the field of chemical synthesis, 1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate serves as a valuable building block for the creation of more complex molecules. Its unique structure can be further modified and functionalized to produce a wide range of chemical products, including specialty chemicals, agrochemicals, and advanced materials.
Used in Research and Development:
Due to its unique chemical properties and potential applications, 1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate is also utilized in research and development laboratories. Scientists and researchers can use this compound to explore new reaction pathways, develop innovative synthetic methods, and investigate its potential interactions with various biological targets.
Check Digit Verification of cas no
The CAS Registry Mumber 199103-19-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,1,0 and 3 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 199103-19:
(8*1)+(7*9)+(6*9)+(5*1)+(4*0)+(3*3)+(2*1)+(1*9)=150
150 % 10 = 0
So 199103-19-0 is a valid CAS Registry Number.
199103-19-0Relevant articles and documents
BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
-
Paragraph 00292, (2020/10/21)
Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of th
NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS
-
, (2019/01/21)
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
-
Paragraph 00413; 00414, (2017/04/11)
Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
